Association of platelet count with all-cause mortality and risk of cardiovascular and respiratory morbidity in stable COPD

Ashraf Fawzy, Julie A. Anderson, Nicholas J. Cowans, Courtney Crim, Robert A Wise, Julie C. Yates, Nadia Hansel

Research output: Contribution to journalArticle

Abstract

Background: Platelet count is a prognostic indicator in the general population and elderly. Thrombocytosis during acute exacerbation of COPD (AECOPD) has been associated with mortality; however, the relationship between platelet count and mortality in stable COPD is unknown. Methods: We performed post hoc secondary analysis on a subsample of 1797 patients in the Study to Understand Mortality and Morbidity in COPD (SUMMIT) who had blood samples drawn at baseline. Participants were current or former smokers, 40-80 years old with moderate COPD and history or increased risk of cardiovascular (CV) disease. The primary outcome was on and post-treatment all-cause mortality. Secondary outcomes included first-on-treatment moderate/severe AECOPD and on-treatment CV composite event (CV death, myocardial infarction, stroke, unstable angina and transient ischemic attack). Multivariable Cox proportional hazards models were used to investigate study endpoint associations with platelet count quintile grouping, continuous platelet count utilizing two-term fractional polynomials, and categories of low, normal and high platelet count (< 150, ≥150 to < 300, ≥300 × 10 9 /L). Results: Patients were followed for 2.3 ± 0.9 years for vital status and 1.6 ± 1.1 years for morbidity endpoints during which 105 (5.8%) died, 651 (36.2%) experienced AECOPD (159 with severe AECOPD) and 86 (4.8%) experienced a CV event. A U-shaped association between platelet count and all-cause mortality was observed. Compared to the third quintile group (Q3) of platelet count, risk of death was increased in the lowest quintile group (Q1; hazard ratio [HR]: 1.73; 95% confidence interval [CI]: 0.93-3.23) and highest quintile group (Q5; HR: 1.66; 95%CI: 0.89-3.10), though point estimates were imprecise. Using clinical cutoffs, compared with normal platelet counts (≥150 to < 300 × 10 9 /L), risk of all-cause mortality was nominally increased among patients with thrombocytopenia (HR: 1.46; 95%CI: 0.81-2.64) and high platelet count (HR: 1.66; 95%CI: 0.96-2.86). Compared with Q3, CV events were nominally increased for Q5 (HR: 1.71; 95%CI: 0.83-3.49) and Q1 (HR: 1.41; 95%CI: 0.70, 2.85). There was no association between platelet count and AECOPD. Conclusions: In stable COPD platelet count demonstrated a U-shaped association with increased risk of 3-year all-cause mortality, though a platelet count level above or below which risk of mortality was increased could not be definitively identified.

Original languageEnglish (US)
Article number86
JournalRespiratory research
Volume20
Issue number1
DOIs
StatePublished - May 8 2019

Fingerprint

Platelet Count
Chronic Obstructive Pulmonary Disease
Morbidity
Mortality
Confidence Intervals
Thrombocytosis
Transient Ischemic Attack
Unstable Angina
Proportional Hazards Models
Thrombocytopenia
Cardiovascular Diseases
Therapeutics
History
Stroke
Myocardial Infarction

Keywords

  • Cardiovascular disease
  • Chronic obstructive pulmonary disease
  • Exacerbations
  • Mortality
  • Platelet count

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Association of platelet count with all-cause mortality and risk of cardiovascular and respiratory morbidity in stable COPD. / Fawzy, Ashraf; Anderson, Julie A.; Cowans, Nicholas J.; Crim, Courtney; Wise, Robert A; Yates, Julie C.; Hansel, Nadia.

In: Respiratory research, Vol. 20, No. 1, 86, 08.05.2019.

Research output: Contribution to journalArticle

Fawzy, Ashraf ; Anderson, Julie A. ; Cowans, Nicholas J. ; Crim, Courtney ; Wise, Robert A ; Yates, Julie C. ; Hansel, Nadia. / Association of platelet count with all-cause mortality and risk of cardiovascular and respiratory morbidity in stable COPD. In: Respiratory research. 2019 ; Vol. 20, No. 1.
@article{4474fbf29b4c4db78b604f3243d188cc,
title = "Association of platelet count with all-cause mortality and risk of cardiovascular and respiratory morbidity in stable COPD",
abstract = "Background: Platelet count is a prognostic indicator in the general population and elderly. Thrombocytosis during acute exacerbation of COPD (AECOPD) has been associated with mortality; however, the relationship between platelet count and mortality in stable COPD is unknown. Methods: We performed post hoc secondary analysis on a subsample of 1797 patients in the Study to Understand Mortality and Morbidity in COPD (SUMMIT) who had blood samples drawn at baseline. Participants were current or former smokers, 40-80 years old with moderate COPD and history or increased risk of cardiovascular (CV) disease. The primary outcome was on and post-treatment all-cause mortality. Secondary outcomes included first-on-treatment moderate/severe AECOPD and on-treatment CV composite event (CV death, myocardial infarction, stroke, unstable angina and transient ischemic attack). Multivariable Cox proportional hazards models were used to investigate study endpoint associations with platelet count quintile grouping, continuous platelet count utilizing two-term fractional polynomials, and categories of low, normal and high platelet count (< 150, ≥150 to < 300, ≥300 × 10 9 /L). Results: Patients were followed for 2.3 ± 0.9 years for vital status and 1.6 ± 1.1 years for morbidity endpoints during which 105 (5.8{\%}) died, 651 (36.2{\%}) experienced AECOPD (159 with severe AECOPD) and 86 (4.8{\%}) experienced a CV event. A U-shaped association between platelet count and all-cause mortality was observed. Compared to the third quintile group (Q3) of platelet count, risk of death was increased in the lowest quintile group (Q1; hazard ratio [HR]: 1.73; 95{\%} confidence interval [CI]: 0.93-3.23) and highest quintile group (Q5; HR: 1.66; 95{\%}CI: 0.89-3.10), though point estimates were imprecise. Using clinical cutoffs, compared with normal platelet counts (≥150 to < 300 × 10 9 /L), risk of all-cause mortality was nominally increased among patients with thrombocytopenia (HR: 1.46; 95{\%}CI: 0.81-2.64) and high platelet count (HR: 1.66; 95{\%}CI: 0.96-2.86). Compared with Q3, CV events were nominally increased for Q5 (HR: 1.71; 95{\%}CI: 0.83-3.49) and Q1 (HR: 1.41; 95{\%}CI: 0.70, 2.85). There was no association between platelet count and AECOPD. Conclusions: In stable COPD platelet count demonstrated a U-shaped association with increased risk of 3-year all-cause mortality, though a platelet count level above or below which risk of mortality was increased could not be definitively identified.",
keywords = "Cardiovascular disease, Chronic obstructive pulmonary disease, Exacerbations, Mortality, Platelet count",
author = "Ashraf Fawzy and Anderson, {Julie A.} and Cowans, {Nicholas J.} and Courtney Crim and Wise, {Robert A} and Yates, {Julie C.} and Nadia Hansel",
year = "2019",
month = "5",
day = "8",
doi = "10.1186/s12931-019-1059-1",
language = "English (US)",
volume = "20",
journal = "Respiratory Research",
issn = "1465-9921",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Association of platelet count with all-cause mortality and risk of cardiovascular and respiratory morbidity in stable COPD

AU - Fawzy, Ashraf

AU - Anderson, Julie A.

AU - Cowans, Nicholas J.

AU - Crim, Courtney

AU - Wise, Robert A

AU - Yates, Julie C.

AU - Hansel, Nadia

PY - 2019/5/8

Y1 - 2019/5/8

N2 - Background: Platelet count is a prognostic indicator in the general population and elderly. Thrombocytosis during acute exacerbation of COPD (AECOPD) has been associated with mortality; however, the relationship between platelet count and mortality in stable COPD is unknown. Methods: We performed post hoc secondary analysis on a subsample of 1797 patients in the Study to Understand Mortality and Morbidity in COPD (SUMMIT) who had blood samples drawn at baseline. Participants were current or former smokers, 40-80 years old with moderate COPD and history or increased risk of cardiovascular (CV) disease. The primary outcome was on and post-treatment all-cause mortality. Secondary outcomes included first-on-treatment moderate/severe AECOPD and on-treatment CV composite event (CV death, myocardial infarction, stroke, unstable angina and transient ischemic attack). Multivariable Cox proportional hazards models were used to investigate study endpoint associations with platelet count quintile grouping, continuous platelet count utilizing two-term fractional polynomials, and categories of low, normal and high platelet count (< 150, ≥150 to < 300, ≥300 × 10 9 /L). Results: Patients were followed for 2.3 ± 0.9 years for vital status and 1.6 ± 1.1 years for morbidity endpoints during which 105 (5.8%) died, 651 (36.2%) experienced AECOPD (159 with severe AECOPD) and 86 (4.8%) experienced a CV event. A U-shaped association between platelet count and all-cause mortality was observed. Compared to the third quintile group (Q3) of platelet count, risk of death was increased in the lowest quintile group (Q1; hazard ratio [HR]: 1.73; 95% confidence interval [CI]: 0.93-3.23) and highest quintile group (Q5; HR: 1.66; 95%CI: 0.89-3.10), though point estimates were imprecise. Using clinical cutoffs, compared with normal platelet counts (≥150 to < 300 × 10 9 /L), risk of all-cause mortality was nominally increased among patients with thrombocytopenia (HR: 1.46; 95%CI: 0.81-2.64) and high platelet count (HR: 1.66; 95%CI: 0.96-2.86). Compared with Q3, CV events were nominally increased for Q5 (HR: 1.71; 95%CI: 0.83-3.49) and Q1 (HR: 1.41; 95%CI: 0.70, 2.85). There was no association between platelet count and AECOPD. Conclusions: In stable COPD platelet count demonstrated a U-shaped association with increased risk of 3-year all-cause mortality, though a platelet count level above or below which risk of mortality was increased could not be definitively identified.

AB - Background: Platelet count is a prognostic indicator in the general population and elderly. Thrombocytosis during acute exacerbation of COPD (AECOPD) has been associated with mortality; however, the relationship between platelet count and mortality in stable COPD is unknown. Methods: We performed post hoc secondary analysis on a subsample of 1797 patients in the Study to Understand Mortality and Morbidity in COPD (SUMMIT) who had blood samples drawn at baseline. Participants were current or former smokers, 40-80 years old with moderate COPD and history or increased risk of cardiovascular (CV) disease. The primary outcome was on and post-treatment all-cause mortality. Secondary outcomes included first-on-treatment moderate/severe AECOPD and on-treatment CV composite event (CV death, myocardial infarction, stroke, unstable angina and transient ischemic attack). Multivariable Cox proportional hazards models were used to investigate study endpoint associations with platelet count quintile grouping, continuous platelet count utilizing two-term fractional polynomials, and categories of low, normal and high platelet count (< 150, ≥150 to < 300, ≥300 × 10 9 /L). Results: Patients were followed for 2.3 ± 0.9 years for vital status and 1.6 ± 1.1 years for morbidity endpoints during which 105 (5.8%) died, 651 (36.2%) experienced AECOPD (159 with severe AECOPD) and 86 (4.8%) experienced a CV event. A U-shaped association between platelet count and all-cause mortality was observed. Compared to the third quintile group (Q3) of platelet count, risk of death was increased in the lowest quintile group (Q1; hazard ratio [HR]: 1.73; 95% confidence interval [CI]: 0.93-3.23) and highest quintile group (Q5; HR: 1.66; 95%CI: 0.89-3.10), though point estimates were imprecise. Using clinical cutoffs, compared with normal platelet counts (≥150 to < 300 × 10 9 /L), risk of all-cause mortality was nominally increased among patients with thrombocytopenia (HR: 1.46; 95%CI: 0.81-2.64) and high platelet count (HR: 1.66; 95%CI: 0.96-2.86). Compared with Q3, CV events were nominally increased for Q5 (HR: 1.71; 95%CI: 0.83-3.49) and Q1 (HR: 1.41; 95%CI: 0.70, 2.85). There was no association between platelet count and AECOPD. Conclusions: In stable COPD platelet count demonstrated a U-shaped association with increased risk of 3-year all-cause mortality, though a platelet count level above or below which risk of mortality was increased could not be definitively identified.

KW - Cardiovascular disease

KW - Chronic obstructive pulmonary disease

KW - Exacerbations

KW - Mortality

KW - Platelet count

UR - http://www.scopus.com/inward/record.url?scp=85065482806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065482806&partnerID=8YFLogxK

U2 - 10.1186/s12931-019-1059-1

DO - 10.1186/s12931-019-1059-1

M3 - Article

C2 - 31068182

AN - SCOPUS:85065482806

VL - 20

JO - Respiratory Research

JF - Respiratory Research

SN - 1465-9921

IS - 1

M1 - 86

ER -